Hans Hammers, M.D., Ph.D.

UT Southwestern Medical Center

Medical Oncologist, Division of Hematology and Oncology

Associate Professor of Internal Medicine

Dr. Hans Hammers, M.D., Ph.D., is a distinguished Professor in the Department of Internal Medicine at UT Southwestern Medical Center, holding the prestigious title of the Eugene P. Frenkel, M.D. Scholar in Clinical Medicine. Originating from Germany, Dr. Hammers embarked on an illustrious academic journey, culminating in his current position as a leader in the field of kidney cancer research and immunotherapy.

 

Educational Background:

Dr. Hammers’ educational pursuits reflect his commitment to advancing medical knowledge. He earned both his medical and doctoral degrees from the Medical University of Luebeck in Germany. Subsequently, he honed his clinical skills during his internal medicine residency at Johns Hopkins Bayview Medical Center in Baltimore. His dedication to medical oncology led him to further specialized training through a fellowship program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University.

 

Education & Training

Residency
The Johns Hopkins Hospital (2002-2005), Internal Medicine
Fellowship
Johns Hopkins University (2005-2009), Medical Oncology
Medical School
Medizinische Hochschule Luebeck, Germany (1992-1999)

 

Honors & Awards

Eugene P. Frenkel Scholar Award 2016, UT Southwestern

 

Professional Associations/Affiliations

Dr. Hammers is an active member of prominent professional organizations, including the American Society of Clinical Oncology, the American Association for Cancer Research, and the Society for Immunotherapy of Cancer. He is also a Board member of KidneyCAN, and he co-chairs the annual Kidney Cancer Research Summit

 

Clinical Expertise:

As the Co-Leader of Clinical Research and Immunotherapy for the Kidney Cancer Research Program, he continues to spearhead efforts in developing novel immunotherapies for kidney cancer, showcasing his commitment to translating research advancements into clinical practice.

 

Leadership & Impact:

As the inaugural Eugene P. Frenkel, M.D. Scholar in Clinical Medicine, Dr. Hammers’ leadership extends beyond research and into shaping the future of clinical practice. His leadership in advancing immunotherapy, particularly with immune checkpoint inhibitors in kidney cancer, garnered national recognition. Dr. Hammers’ contributions extended beyond research, as he served as the principal investigator for numerous industry- and investigator-sponsored trials, solidifying his role as a trailblazer in the field.

Dr. Hans Hammers’ unwavering commitment to advancing clinical practice, coupled with his leadership and recognition in the field, positions him as a pivotal figure in the fight against kidney cancer, making him an invaluable asset to both UT Southwestern and the broader landscape of oncology.

“Many oncologists in the community may see only one or two kidney cancer patients a year. I am focused on this disease.” 

Naomi Haas, MD | Kidney Cancer Research Consortium

Naomi Haas

UPenn

Daniel George, MD | Kidney Cancer Research Consortium

Daniel George

Duke University

Eric Jonasch, M.D. | Kidney Cancer Research Consortium

Eric Jonasch

MD Anderson

David McDermott, MD | Kidney Cancer Research Consortium

David McDermott

Beth Israel

Brian Rini, MD | Kidney Cancer Research Consortium

Brian Rini

Vanderbilt University

Ulka Vaishampayan, MD | Kidney Cancer Research Consortium

Ulka Vaishampayan

University of Michigan